This review highlights novel dual and triple agonists for obesity and type 2 diabetes management, suggesting improved glycemic control and weight loss.
Key Points
Novel dual and triple agonists showed potential for enhancing glycemic control and weight management in patients with type 2 diabetes and obesity.
GLP-1, GIP, and glucagon combinations may provide cardioprotective and anti-inflammatory benefits, enhancing overall metabolic health.
Evidence indicates these agonists can leverage multiple metabolic pathways, promoting both weight loss and glycemic control effectively.
The treatment safety profiles are crucial for assessment, necessitating careful evaluation due to potential adverse effects.